CANF — Can Fite Biopharma Share News
0.000.00%
Last trade - 00:00- $4.92m
- $1.93m
- $0.41m
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage
Brief: Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
Can-Fite Biopharma surges as pancreatic cancer drug meets main goal in study
Brief: Can-Fite Completes Patient Enrollment In Phase 2A Pancreatic Cancer Study Of Namodenoson
Board Approved A 1-For-3,000 Reverse Split Of Company's Ordinary Shares
Brief: Can-Fite Provides Update On Clinical And Financial Status
Brief: Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson
Brief: Can-Fite Announces $3.0 Million Registered Direct Offering Of American Depositary Shares
Brief: Can-Fite Reports 2024 Financial Results And Clinical Update
Brief: Can-Fite Anti-Obesity Drug Namodenoson Received Patent Allowance In Australia
Brief: Can Fite Pancreatic Carcinoma Phase IIa Study With Namodenoson Got Authorization From Israeli Ministry Of Health
Brief: Can-Fite Provides Namodenoson Patent Update
Brief: Can-Fite Applies For FDA Orphan Drug Designation For Namodenoson In The Treatment Of Pancreatic Cancer
Brief: Can Fite Biopharma Findings Demonstrate Namodenoson Anti-Cancer And Protective Effect Mechanism
Brief: Can-Fite Received Notice Of Allowance From The European Patent Office For The Treatment Of Erectile Dysfunction With Cf602
Brief: Can-Fite Submits IND Application To FDA To Conduct Phase IIb Clinical Trial Of Namodenoson In MASH Patients